For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- MHLW Council OKs Public Knowledge-Based Applications for FOLFOX Therapy for Stomach Cancer
September 2, 2022
- Experts Raise Alarm on Declining Attractiveness of Japan Market: New Panel
September 1, 2022
- New Expert Panel on Drug Distribution and Pricing Boots Up; 2-Step Proposals Eyed for Off-Year Revision, 2024 Reform
September 1, 2022
- PM Kishida Vows Earlier Rollout of Omicron Boosters
September 1, 2022
- MHLW Orders Label Revisions for Cyramza, Plaquenil
September 1, 2022
- Japan Mulls Moving Up Omicron Boosters to September
August 31, 2022
- University of Tokyo Selected as Flagship R&D Site to Orchestrate Japan’s Vaccine Efforts: SCARDA Project
August 31, 2022
- Japan Approves AstraZeneca’s COVID-19 Cocktail Therapy Evusheld
August 30, 2022
- Pfizer’s COVID Booster Approved for Children Aged 5-11 in Japan
August 30, 2022
- LDP Group Eyes Proposal on Generic Distribution, Pricing; Expert Wants Penalty on Healthcare Providers Getting Undue Discounts
August 30, 2022
- AZ’s Asthma Drug Tezepelumab Clears MHLW Panel Review; BMS’ Psoriasis Med, MSD/Sanofi Jabs Too
August 30, 2022
- AstraZeneca’s COVID Cocktail in Line for Approval, Comirnaty Booster for Ages 5-11
August 30, 2022
- Japan Eyes FY2023 Launch of Pandemic Response Agency
August 29, 2022
- MHLW’s Health Service Bureau to Seek Funding for “Income Security System” for Antimicrobials for FY2023
August 29, 2022
- MHLW’s Health Policy Bureau to Seek Budget for Research into Integrating Drug Supply Info, Clarification of Generic Ratio
August 29, 2022
- MHLW Begins Discussions on Potential Use of Non-Doctor/Nurse Healthcare Professionals as Vaccinators
August 29, 2022
- MHLW’s Pharma Bureau to Request Budget to Promote RWD Use in Regulatory Filing for FY2023
August 26, 2022
- MHLW to Seek 400 Million Yen for AI-Powered Drug Discovery for Cancer: FY2023 Budget Request
August 26, 2022
- MHLW Seeks 2-Year Extension of Raise on R&D Tax Credit Ceiling: FY2023 Reform Request
August 26, 2022
- MHLW’s Health Policy Bureau Eyes COI Management System, Upgraded Clinical Research Database: FY2023 Budget Request
August 26, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…